These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30863093)

  • 1. Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from Phase III randomized trials.
    Yin Z; You J; Wang Y; Zhao J; Jiang S; Zhang X; Wang P; Tao Z; Wang X; Yuan Z
    Onco Targets Ther; 2019; 12():1259-1268. PubMed ID: 30863093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer.
    Kim S; Kong JH; Lee Y; Lee JY; Kang TW; Kong TH; Kim MH; You SH
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012817. PubMed ID: 36884035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionation for clinically localized prostate cancer.
    Hickey BE; James ML; Daly T; Soh FY; Jeffery M
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late toxicity rates following definitive radiotherapy for prostate cancer.
    Ohri N; Dicker AP; Showalter TN
    Can J Urol; 2012 Aug; 19(4):6373-80. PubMed ID: 22892261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genitourinary and gastrointestinal toxicity among patients with localized prostate cancer treated with conventional versus moderately hypofractionated radiation therapy: systematic review and meta-analysis.
    Carvalho ÍT; Baccaglini W; Claros OR; Chen FK; Kayano PP; Lemos GC; Weltman E; Kuban DA; Carneiro A
    Acta Oncol; 2018 Aug; 57(8):1003-1010. PubMed ID: 29882448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity after moderately hypofractionated versus conventionally fractionated prostate radiotherapy: A systematic review and meta-analysis of the current literature.
    Francolini G; Detti B; Becherini C; Caini S; Ingrosso G; Di Cataldo V; Stocchi G; Salvestrini V; Lancia A; Scartoni D; Giacomelli I; Sardaro A; Carbonara R; Borghesi S; Aristei C; Livi L
    Crit Rev Oncol Hematol; 2021 Sep; 165():103432. PubMed ID: 34352361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials.
    Royce TJ; Lee DH; Keum N; Permpalung N; Chiew CJ; Epstein S; Pluchino KM; D'Amico AV
    Eur Urol Focus; 2019 Jul; 5(4):577-584. PubMed ID: 29221876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moderate hypofractionated radiotherapy is more effective and safe for localized prostate cancer patients: a meta-analysis.
    Cao L; Yang YJ; Li ZW; Wu HF; Yang ZC; Liu SX; Wang P
    Oncotarget; 2017 Jan; 8(2):2647-2658. PubMed ID: 27926521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderate hypofractionated helical tomotherapy for older patients with localized prostate cancer: long-term outcomes of a phase I-II trial.
    Cui D; Du L; Yu W; Cai B; Meng L; Yang J; Luo Y; Chen J; Ma L
    Radiol Oncol; 2022 Mar; 56(2):216-227. PubMed ID: 35344645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up.
    Hou Z; Li G; Bai S
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1063-71. PubMed ID: 25173623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderately Hypofractionated Radiotherapy with Simultaneous Integrated Boost in Prostate Cancer: A Comparative Study with Conventionally Fractionated Radiation.
    Cante D; Piva C; Petrucci ETF; Sciacero P; Ferrario S; Pasquino M; Casanova Borca V; La Porta MR; Franco P
    J Oncol; 2020; 2020():3170396. PubMed ID: 33312201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional Versus Hypofractionated Radiation Therapy for Localized or Locally Advanced Prostate Cancer: A Systematic Review and Meta-analysis along with Therapeutic Implications.
    Datta NR; Stutz E; Rogers S; Bodis S
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):573-589. PubMed ID: 29280452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
    Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
    Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal scheduling of hypofractionated radiotherapy for localized prostate cancer: A systematic review and metanalysis of randomized clinical trials.
    Arcangeli G; Arcangeli S; Pinzi V; Benassi M; Benassi M; Strigari L
    Cancer Treat Rev; 2018 Nov; 70():22-29. PubMed ID: 30053726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
    Lee WR; Dignam JJ; Amin MB; Bruner DW; Low D; Swanson GP; Shah AB; D'Souza D; Michalski JM; Dayes IS; Seaward SA; Hall WA; Nguyen PL; Pisansky TM; Faria SL; Chen Y; Rodgers JP; Sandler HM
    J Clin Oncol; 2024 Jul; 42(20):2377-2381. PubMed ID: 38759121
    [No Abstract]   [Full Text] [Related]  

  • 16. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
    Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for the treatment of metastatic extradural spinal cord compression in adults.
    George R; Jeba J; Ramkumar G; Chacko AG; Tharyan P
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD006716. PubMed ID: 26337716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
    Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.